Galectin Therapeutics Inc. (NASDAQ:GALT)

CAPS Rating: 1 out of 5

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.

Recs

0
Player Avatar jwray01 (99.63) Submitted: 8/4/2012 1:47:28 AM : Underperform Start Price: $2.10 GALT Score: -91.21

spammed heavily

Featured Broker Partners


Advertisement